The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma.
 
Soo Park
Consulting or Advisory Role - Regeneron; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Regeneron (Inst); Replimune (Inst)
 
Omid Najmi
Employment - Bristol-Myers Squibb
 
Jennifer Chang
No Relationships to Disclose
 
Tuyet Tan
No Relationships to Disclose
 
Poorva Vaidya
Consulting or Advisory Role - Immunocore
 
Warren Chow
Research Funding - Regeneron
Other Relationship - Advenchen Laboratories; InhibRx
 
Adil Daud
Stock and Other Ownership Interests - Neuvogen; Trex bio
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Genoptix; GlaxoSmithKline; Merck; Oncosec; Pfizer
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering Plough (Inst); Novartis; oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Gregory Daniels
Research Funding - BioAtla (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); IDEAYA Biosciences (Inst); Imugene (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Replimune (Inst)
 
Silvia Boffo
Employment - Bristol Myers Squibb Foundation